Oral etoposide for treatment and/or maintenance treatment of recurrent epithelial ovarian cancer

Okunade, Kehinde Sharafadeen; Akinsete, Adeseye Michael; Salako, Omolola; Afolabi, Bosede Bukola; Neal, Richard D; Gynaecological, Neuro‐oncology Cochrane

doi:10.1002/14651858.cd013537

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The principal chemotherapeutic effect of etoposide lies in the fact that the permanent double-strand breaks overwhelm the cells thereby initiating cell deaths ( Figure 3A ). Thus, etoposide changes topoisomeraseII from an important enzyme to a strong cellular toxin that induces breaks in the genome facilitating mutagenesis and cell death pathways(27). However, other mechanisms, such as chromosomal aberrations, aneuploidy, and endoreplication, may, nevertheless, play a role in cancer cells’ sensitivity to etoposide (28,29).…”

Section: Introductionmentioning

confidence: 99%

Elevated levels of lamin A promote HR and NHEJ-mediated repair mechanisms in etoposide-treated ovarian cancer cells

Sengupta

2022

Preprint

View full text Add to dashboard Cite

Lamins are emerging as major regulators in the maintenance of nuclear architecture and genome organization. Extensive research for the last two decades has enormously contributed to understanding the roles of lamins in various signaling mechanisms which are drastically modified in neoplasia. It is interesting to record that alteration in lamin A/C expression and distribution drives tumorigenesis of almost all tissues of human bodies. One of the important signatures of a cancer cell is its inability to repair DNA damage which befalls several genomic events that transform the cells to be sensitive to chemotherapeutic agents. This genomic and chromosomal instability is the most common feature found in cases of high-grade ovarian serous carcinoma. Here, we report elevated levels of lamins in OVCAR3 cells (High grade ovarian serous carcinoma cell line) in comparison to IOSE (Immortalised ovarian surface epithelial cells) and consequently altered damage repair machinery in OVCAR3. We have analyzed the changes in global gene expression as a sequel to DNA damage induced by etoposide in ovarian carcinoma where lamin A is particularly elevated in expression and reported some differentially expressed genes associated with pathways conferring cellular proliferation and chemoresistance. We highlight new avenues unraveling the role of upregulated lamin A in confronting chemically induced genomic instability in the context of high grade ovarian serous cancer through a combination of HR and NHEJ mechanisms.

show abstract

Section: Introductionmentioning

confidence: 99%

Elevated levels of lamin A promote HR and NHEJ-mediated repair mechanisms in etoposide-treated ovarian cancer cells

Sengupta

2022

Preprint

View full text Add to dashboard Cite

show abstract

“… 8 Ovarian cancer is the fifth leading cause of death from cancer among women (184 799 deaths in 2018) and is the most lethal gynecologic malignancy. 9 - 11 Approximately 68% of the cases are diagnosed at the late stage, leading to a reduction in their survival rates compared to those diagnosed at an earlier stage. 12 Therefore, in most cases, they are diagnosed at a late stage, which may not be treated, leading to undesirable prognosis.…”

Section: Introductionmentioning

confidence: 99%

In vitro Assessment of Magnetic Liposomal Paclitaxel Nanoparticles as a Potential Carrier for the Treatment of Ovarian Cancer

et al. 2020

View full text Add to dashboard Cite

Purpose: This study aimed to evaluate the role of magnetic liposome nanoparticles (ML NPs) as a carrier for paclitaxel (PTX) for the treatment of ovarian cancer in vitro . Methods: Magnetic NPs (MNPs) were synthesized by chemical co-precipitation method. The resulting NPs were characterized in terms of size, size distribution, zeta potential, drug encapsulation efficiency (EE), drug release pattern, and cytotoxicity effects. Results: The size and zeta potential of PTX-PEG-L and PTX-PEG-ML NPs were determined to be 296, 198 nm; -20, and -19 mV, respectively. Also, their drug encapsulation efficiencies were determined to be 97% and 96%, respectively. It was found that PTX-PEG-ML NPs, compared to PTX-PEG-L NPs, caused a reduction (11%) in the rate of drug release. The cytotoxicity of the drug-loaded NPs was assessed using 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay against human ovarian epithelial cancer (A2780CP) cells, and the results demonstrated that PTX-PEG-ML NPs caused higher cytotoxicity (by 14%) compared to PTX-PEG-L NPs (IC 50 : 1.88 ± 0.09 and 2.142 ± 0.1 µM, respectively). Conclusion: Overall, the results of this study suggest that PTX-PEG-ML NPs could be considered as a therapeutic candidate for the treatment of ovarian cancer.

show abstract

Chemotherapeutic Protocols for the Treatment of Gynecological Cancer

Cavalcanti

2022

Chemotherapy Protocols and Infusion Sequence

View full text Add to dashboard Cite

Oral etoposide for treatment and/or maintenance treatment of recurrent epithelial ovarian cancer

Cited by 4 publications

References 37 publications

Elevated levels of lamin A promote HR and NHEJ-mediated repair mechanisms in etoposide-treated ovarian cancer cells

Elevated levels of lamin A promote HR and NHEJ-mediated repair mechanisms in etoposide-treated ovarian cancer cells

In vitro Assessment of Magnetic Liposomal Paclitaxel Nanoparticles as a Potential Carrier for the Treatment of Ovarian Cancer

Chemotherapeutic Protocols for the Treatment of Gynecological Cancer

Contact Info

Product

Resources

About